

BILL SUMMARY
1st Session of the 55th Legislature

Bill No.:	HB1074
Version:	Committee Substitute
Request Number:	7050
Author:	Rep. Morrisette
Date:	3/2/2015
Impact:	Please see previous summary of this measure

Research Analysis

The CS for HB 1074 specifies that an investigational drug, biological product, or device may be made available through a pharmacy.

The measure permits an eligible patient, as defined in the measure, to try an investigational drug, biological product, or device that has successfully completed phase one of an FDA clinical trial and remains under an approved investigation. The measure does not require a manufacturer to make such products available to an eligible patient, and an insurer may provide coverage for such products. A licensing board may not take action against a provider based solely on their recommendations to an eligible patient regarding access to or treatment with such products. Additionally, the measure does not create a private cause of action against a manufacturer or against any other person or entity involved in the care of an eligible patient using such products.

Prepared By: Scott Tohlen

Fiscal Analysis

Upon review of the measure, it has been determined to have no measureable revenue or fiscal considerations.

Prepared By: Mark Tygret

Other Considerations

None.